Scott S Tykodi

ORCID

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 4

Top Venues

BMJ open

Clinical cancer research : an official journal of the American Association for Cancer Research

Human vaccines & immunotherapeutics

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Daniel J George, David R Spigel, Lucio N Gordan, Samith T Kochuparambil, Ana M Molina, Jeff Yorio, Arash Rezazadeh Kalebasty, Heidi McKean, Nishan Tchekmedyian, Scott S Tykodi, Joshua Zhang, Margarita Askelson, Jennifer L Johansen, Thomas E Hutson
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. BMJ open 12 (9) (2022)
Timothy Anthony Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Scott S Tykodi, Osama E Rahma, Tanguy Y Seiwert, Kyriakos P Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jimenez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J Harvey
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (17) (2022)
Scott S Tykodi, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Michael R Harrison, Ivor Percent, Rakesh Singal, Peter Van Veldhuizen, Daniel J George, Thomas Hutson, Joshua Zhang, Jesus Zoco, Jennifer L Johansen, Arash Rezazadeh Kalebasty
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. Journal for immunotherapy of cancer 10 (2) (2022)
Yuexin Xu, Chris P Miller, Edus H Warren, Scott S Tykodi
Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma. Human vaccines & immunotherapeutics 17 (7) (2021)

Scott S Tykodi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Scott S Tykodi